US Research Published: Week ending on May 8, 2026

研报英文原文证据摘录

US Research Published: Week ending on May 8, 2026

y, Jason

Royalty Pharma: Strong execution on display & RPRX well positioned to win in drug royalty space Gerberry, Jason

United Therapeutics Corporation: New inhaler too early to value; IPF launch vs. base competition

balances risk-reward Gerberry, Jason

4D Molecular Therapeutics, Inc.: 4D-150 in wAMD advancing ahead of key pivotal readouts in

2027; Reiterate Buy Giraldo, Daniel

Biohaven, Ltd.: 1Q26 EPS: lower PO to reflect spend, pipe value. Reit Neutral on balanced

risk:reward Ramadane, Dina

Aktis Oncology: AKY-2519 trials logical: optionality on registration path, broader platform upside Stranahan, Alec

CG Oncology: Core thesis still strong ahead of PIVOT-006 IR NMIBC data Stranahan, Alec

CRISPR Therapeutics: Solid progress on Casgevy, pipeline fronts ahead of value-unlocks in 2H26e Stranahan, Alec

Krystal Biotech: Encouraging ex-US trends round off solid 1Q26 with focus shifting to ex-US,

pipeline Stranahan, Alec

Novavax: Progress on leaner operating model in 1Q26, early on value conversion Stranahan, Alec

Revolution Medicines: All cylinders firing with RAS(ON) franchise, ASCO presentation the next

spotlight Stranahan, Alec

TG Therapeutics: Solid 1Q26e, competitor data a key focus heading into 2H26e Stranahan, Alec

Xencor: TL1A franchise looks compelling, later phase data needed for value unlock Stranahan, Alec

Biogen Inc.: SubQ lecanemab PDUFA extension a setback but approval still likely Zemansky, Jason

BridgeBio Pharma: Repositioning for a rerate; Our thoughts post the 1Q call Zemansky, Jason

Cytokinetics, Incorporated: ACACIA: Winning the battle but the war is… much less clear; PO to $83 Zemansky, Jason

Cytokinetics, Incorporated: ACACIA’s hits: approvable, but the endpoints raise questions Zemansky, Jason